A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Hypogonadism
- Sponsor
- GlaxoSmithKline
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- Safety measured by: monitoring laboratory tests changes in blood pressure and heart rate and heart activity on an ECG machine
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the effect of 28-day repeat dosing of this combination with varying BID doses of testosterone (T), in combination with a fixed BID dose of dutasteride (D), as well as a testosterone alone arm, on T and D levels in the blood. The rationale is to look for the effects of each compound on the other, and to look for any safety problems that may result when the 2 drugs are given together.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Safety measured by: monitoring laboratory tests changes in blood pressure and heart rate and heart activity on an ECG machine
Time Frame: days 1 and 28
Secondary Outcomes
- Pharmacokinetics of testosterone, DHT, estradiol, estrone & dutasteride(days 1 and 28.)
- Testosterone concentration .(on days 1 and 28)
- Anabolic & androgenic Pharmacodynamic biomarkers(pre- and post-dose)